South Korea Diabetes Drugs Market Insight
Published: 25 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The market for diabetic medications in South Korea is anticipated to expand at a compound annual growth rate (CAGR) of 11.17% due to increased diabetes prevalence, and GLP-1/SGLT-2 innovation.
South Korea Diabetes Drugs Market Insights Forecasts to 2035
- The South Korea Diabetes Drugs Market Size Was Estimated USD 1.90 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 11.17% from 2025 to 2035
- The South Korea Diabetes Drugs Market Size is Expected to rise around USD 5.48 Billion by 2035
Notable Insights for the South Korea Diabetes Drugs Market
- Oral antidiabetics have the part of the market when we look at the different types of drugs, but GLP-1 receptor agonists and SGLT-2 inhibitors are growing fast because they help people lose weight.
- Pharmacies in hospitals are where people usually get their medicine. Now that more prescriptions are being filled outside of hospitals and online, regular pharmacies and internet pharmacies are getting more business.
- In year 2023 the government of South Korea said that National Health Insurance Service or NHIS must cover all medicines for people with diabetes. Then in 2025 Eli Lilly said they would put USD 500 million.
- When we just look at medicines for type 2 diabetes the market got bigger by 8% every year for five years and by 2023 it was worth, around KRW 1.5 trillion (USD 1.1 billion).
Download the eBook (ToC)
Why Buy This Report
- This study is helpful for people who want to make decisions about diabetes care. It says that by 2025 the diabetes care market will be worth about USD 1.90 billion by 2035.
- The study looks at the diabetes care market in a lot of detail. It helps people who're interested in diabetes care find the areas that are growing the fastest, like GLP-1 and SGLT-2 inhibitors.
- The study also looks at the companies that're already big players in the diabetes care market. It tells us about what these companiesre doing and what the current rules and laws are.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the South Korea diabetes drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in South Korea Diabetes Drugs Market
- LG Chem
- Hanmi Pharmaceutical
- JW Pharmaceutical
- HK inno.N Corporation
- Kyungdong Pharmaceutical
- Daewoong Pharmaceutical
- Chong Kun Dang
- Yuhan Corporation
- Boryung Pharmaceutical
- Green Cross Corporation
Recent Developments:
- In June 2025, the company showed it is really committed to finding ways to treat endocrine problems by working with other companies to study diseases that affect metabolism.
- In April 2025, introduced an improved chronic illness management platform that provides integrated digital health services and pharmaceutical management solutions to help diabetes treatment.
Market Segmentation:
South Korea Diabetes Drugs Market, By Drug Class
- Insulins
- Oral Antidiabetics
- GLP-1 Receptor Agonists
- Combination Therapies
South Korea Diabetes Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online/E-Pharmacies
- Wholesalers
South Korea Diabetes Drugs Market, By End-User
- Hospitals
- Clinics
- Home Care Settings
- Pharmacies
Expert Views:
The South Korea diabetes drugs market is going to get big because more people are getting diabetes. This is also happening because doctors are using GLP-1 receptor agonists and SGLT-2 inhibitors a lot now. It is good that the government is helping people pay for these medicines. The South Korea diabetes drugs market companies that focus on making treatments will be the best ones, until 2035.
Author: Govind and Krishna By Decisions Advisors and Consulting